Effects of Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor on Diabetic Lower Extremity Ulcers: Case Series of Nine Patients
Xiaoling Zhang,Jing Tao,Song Gong,Xuefeng Yu,Shiying Shao
DOI: https://doi.org/10.2147/dmso.s461349
2024-05-07
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Xiaoling Zhang, 1, 2 Jing Tao, 1, 2 Song Gong, 1, 2 Xuefeng Yu, 1, 2 Shiying Shao 1, 2 1 Division of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, People's Republic of China; 2 Branch of National Clinical Research Center for Metabolic Diseases, Wuhan, Hubei Province, People's Republic of China Correspondence: Shiying Shao, Division of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Jiefang Road 1095, Wuhan, Hubei Province, 430030, People's Republic of China, Tel +86-13627144576, Fax +86-27-83662883, Email Background: Diabetic lower extremity ulcer, including diabetic foot ulcer (DFU) and leg ulcer, is one of the refractory complications of diabetes, the treatment of which is challenging, expensive, and lengthy. Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor (rhGM-CSF) is an immunomodulatory cytokine that has been mainly applied in the treatment of hematological diseases. Clinical evidence regarding GM-CSF in the treatment of diabetic lower extremity ulcers is limited. This study is the first case series that investigates the repurpose effects of rhGM-CSF on diabetic ulcer healing in real clinical practice. Methods: Nine patients diagnosed with diabetes and refractory lower extremity ulcer (ulcer duration ≥ 2 weeks) were included from September 2021 to February 2023 in the Division of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Patients with Wagner grade ≥ 4 and SINDAD ≥ 5 were excluded. The included subjects were treated with rhGM-CSF plus standard of care (SOC) including glycemic control, foot care education, debridement of necrotic tissues, topical wound dressings, offloading, and infection control when necessary. The observation endpoint was complete epithelialization. Their clinical manifestations, laboratory tests, and therapeutic effects were extracted and analyzed. Results: The case series included 9 cases aged from 29 to 80 years and all the patients were male. Seven of 9 patients presented neuropathic ulcer. Only one case showed non-infected ulcer from tissue samples and one case presented ankle brachial index (ABI) < 0.9. It was observed that the ulcer areas among these 9 patients gradually declined throughout the whole treatment period with the average healing velocity 0.32 ± 013 cm 2 /day and the mean time to complete healing 16.0 ± 3.7 days. The relative area (percentage of initial ulcer area) decreased to 66.7 ± 13.0% on average after the first treatment. Ulcers in all the 9 patients achieved complete epithelialization after 4– 8 times treatments. Conclusion: The case series suggests rhGM-CSF as a promising therapeutic strategy for the treatment of diabetic ulceration. More robust data from randomized controlled trials are required to further evaluate its clinical efficacy. Keywords: recombinant human granulocyte/macrophage colony-stimulating factor, diabetic lower extremity ulcer, diabetic foot ulcer Diabetic lower extremity ulcer, including diabetic foot ulcer (DFU) and leg ulcer, is a common, complex, disabling, and costly complication of diabetes. 1 It is estimated that 19–34% of patients with diabetes develop a foot ulcer in their lifetime. 1 Patients with DFUs are at increased risk for recurrence, and the rates at 1, 3, and 5 years were 40%, 60%, and 65%, respectively, according to 19 compatible studies. 1 In addition, diabetic ulcers also cause a huge socio-economic burden worldwide. 2 It was reported that direct costs for diabetes in the USA were $237 billion in 2017, about one-third of which was attributable to DFU. 3 The standard of care (SOC) of diabetic ulcers consists of blood glucose and infection control, debridement of necrotic tissues, revascularization, mechanical offloading, dressing change, and foot care education. 4 However, the effect of these multidisciplinary approaches on wound healing could not completely meet clinical needs. 5,6 It has been reported that the median healing time of DFUs was 76 days for male patients and 117 days for female patients, according to a clinical study among 1,488,201 hospitalized patients in China. 5 In addition, the healing percentage of diabetic ulcer in our hospital was approximately 70% after 1 month when patients were only undertaken standard treatment (unpublished data). Therefore, some new adjunctive therapies are needed to promote the healing of DFUs. Hemopoietic colony stimulating factors (CSFs), including Granulocyte-CSF (G- -Abstract Truncated-
endocrinology & metabolism